Stockscreener 앱 받기
2.95
5.75%
-0.18
시간 외 거래:
2.97
0.02
+0.68%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
How Iovance Biotherapeutics Inc. stock performs during market volatilitySwing Entry Risk Mitigation with Chart Analysis - Newser
Intraday pattern recognizer results for Iovance Biotherapeutics Inc.Weekly Market Direction and Sector Summary - Newser
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank of New York Mellon Corp - Defense World
Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Kilgore News Herald
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - metal.it
Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com
Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛
Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest
Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire
About Us - FinancialContent
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics Benefits from Replimune FDA Setback, Maintains Buy Rating - AInvest
Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative
Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView
Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest
Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade
Positive Week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Institutional Investors Who Lost 64% Over the Past Year - 富途牛牛
Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com
Where are the Opportunities in (IOVA) - news.stocktradersdaily.com
What drives Iovance Biotherapeutics Inc. stock priceFast-track wealth growth - jammulinksnews.com
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Iovance Biotherapeutics Shares Soar 14.46% on FDA Approval, Leadership Changes - AInvest
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest
Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
Iovance Stock Rises as Amtagvi’s Success Boost Morale - timothysykes.com
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - The Globe and Mail
Teacher Retirement System of Texas Has $191,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Hold” by Analysts - Defense World
Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia
Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World
What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com
Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade
Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com
Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade
Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
1.32%
1.06%
자본화:
|
볼륨(24시간):